医師の一分

アクセスカウンタ

zoom RSS HPVウイルスが咽頭癌の3分の1に関連

<<   作成日時 : 2013/08/08 21:47   >>

ブログ気持玉 0 / トラックバック 0 / コメント 0

HPVウイルスが咽頭癌の3分の1に関連
 HPVには100以上の種類があるが、16と18の2つが癌を引きおこす可能性が高い。HPV-16は子宮頚癌の薬60%、肛門の癌の80%、口腔癌の60%の原因であるとされる。
 英国では毎年約1,500人が咽頭癌と診断され、470人近くが死亡している。

-----------------------
HPVウイルスにより年に25,000人のガンが発症/米国 CDC
http://kurie.at.webry.info/200811/article_8.html
HPVによる男性の上咽頭癌の増加
http://kurie.at.webry.info/200802/article_9.html

------------------------------------------------------
20 July 2013 Last updated at 23:22 GMT
HPV virus 'linked to third of throat cancer cases'
http://www.bbc.co.uk/news/health-23374920

One third of people diagnosed with throat cancer are infected with a form of the HPV virus, a study suggests.
HPV (human papillomavirus) is the major cause of cervical cancer, and the virus is known to spread through genital or oral contact.
Actor Michael Douglas is reported to have spoken about the link after his own diagnosis with throat cancer.
Experts said this study in the Journal of Clinical Oncology, which quantifies the link, showed "striking" results.
There are more than 100 types of HPV. Most people will be infected with HPV at some point, but in most the immune system will offer protection.
There are two HPV strains which are most likely to cause cancer - HPV-16 and HPV-18.
HPV-16 is thought to be responsible for around 60% of cervical cancers, 80% of cancers in the anus and 60% of oral cancers.
Around 1,500 people are diagnosed with throat cancers each year in the UK, with around 470 people dying from the disease.

Survival benefit
This study looked at HPV's link with cancer of the back of the throat - oropharyngeal cancer.
It looked at blood test results collected from people who took part in a huge prospective study into lifestyle and cancer, who were all healthy at the start.
Everyone gives a blood sample when they join the study, and in this case the researchers were able to check for the presence of antibodies to one of HPV's key proteins - E6.

E6 knocks out part of cells' protection system, which should prevent cancer developing.
Having the antibodies means HPV has already overcome that defence and caused cancerous changes in cells.
The researchers compared blood test results - some more than 10 years old - for 135 people who went on to develop throat cancer and for 1,599 cancer-free people.
The University of Oxford team found 35% of those with throat cancer had the antibodies, compared with fewer than 1% of those who were cancer-free.
However, these patients were more likely to survive throat cancer than people whose disease had other causes, such as alcohol or tobacco use.
The study found 84% of people with the antibodies were still alive five years after diagnosis, compared with 58% of those without.

Broader effect?
Dr Ruth Travis, a Cancer Research UK scientist at Oxford who worked on the study, said: "These striking results provide some evidence that HPV-16 infection may be a significant cause of oropharyngeal cancer."
Sara Hiom, Cancer Research UK's director of health information, said: "HPV is an extremely common virus.
"Practising safer sex may reduce the risk of getting or passing on HPV, but condoms won't stop infections completely."
She added: "If the HPV vaccine can also protect against oral HPV infections and cancers, then it could have a broader potential protective effect, but we don't have enough research yet to tell us. "

------------------------------------------------------
J Clin Oncol. 2013 Jul 1. [Epub ahead of print]
Evaluation of Human Papillomavirus Antibodies and Risk of Subsequent Head and Neck Cancer.
Kreimer AR, et al

Abstract
PURPOSEHuman papillomavirus type 16 (HPV16) infection is causing an increasing number of oropharyngeal cancers in the United States and Europe. The aim of our study was to investigate whether HPV antibodies are associated with head and neck cancer risk when measured in prediagnostic sera. METHODSWe identified 638 participants with incident head and neck cancers (patients; 180 oral cancers, 135 oropharynx cancers, and 247 hypopharynx/larynx cancers) and 300 patients with esophageal cancers as well as 1,599 comparable controls from within the European Prospective Investigation Into Cancer and Nutrition cohort. Prediagnostic plasma samples from patients (collected, on average, 6 years before diagnosis) and control participants were analyzed for antibodies against multiple proteins of HPV16 as well as HPV6, HPV11, HPV18, HPV31, HPV33, HPV45, and HPV52. Odds ratios (ORs) of cancer and 95% CIs were calculated, adjusting for potential confounders. All-cause mortality was evaluated among patients using Cox proportional hazards regression.ResultsHPV16 E6 seropositivity was present in prediagnostic samples for 34.8% of patients with oropharyngeal cancer and 0.6% of controls (OR, 274; 95% CI, 110 to 681) but was not associated with other cancer sites. The increased risk of oropharyngeal cancer among HPV16 E6 seropositive participants was independent of time between blood collection and diagnosis and was observed more than 10 years before diagnosis. The all-cause mortality ratio among patients with oropharyngeal cancer was 0.30 (95% CI, 0.13 to 0.67), for patients who were HPV16 E6 seropositive compared with seronegative. CONCLUSIONHPV16 E6 seropositivity was present more than 10 years before diagnosis of oropharyngeal cancers.

テーマ

関連テーマ 一覧


月別リンク

ブログ気持玉

クリックして気持ちを伝えよう!
ログインしてクリックすれば、自分のブログへのリンクが付きます。
→ログインへ

トラックバック(0件)

タイトル (本文) ブログ名/日時

トラックバック用URL help


自分のブログにトラックバック記事作成(会員用) help

タイトル
本 文

コメント(0件)

内 容 ニックネーム/日時

コメントする help

ニックネーム
本 文
HPVウイルスが咽頭癌の3分の1に関連 医師の一分/BIGLOBEウェブリブログ
文字サイズ:       閉じる